sPARK.
2018

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, …

JAMA Oncology 4(8), 1080–1084

Wungki Park
NSCLCHealth Economics
142Citations
2018Year

Related by topic

Publication · NSCLCClinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancerPublication · NSCLCOutcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortProject / Trial · NSCLCSetidegrasib (ASP3082)Publication · NSCLCSetidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Local graph

Tap a node to select · use + / − to zoom · enable Move graph to drag

Browse nodes (4)
Open full graph →